AUM Biosciences, C-CAMP join hands for cancer therapy

The Centre for Cellular and Molecular Platforms (C-CAMP) has partnered with AUM Biosciences, a Singapore-based biotechnology company to develop small-molecule candidates for cancer therapy.

Singapore, 13 November 2018 – The Centre for Cellular and Molecular Platforms (C-CAMP), India’s premier bio-innovation hub has signed an agreement with AUM Biosciences, a Singaporebased biotechnology company to strengthen its focus on the pre-clinical development of small-molecules as anti-cancer drugs. The agreement recognises AUM as one of CCAMP’s first international incubatees.

Under this collaboration, C-CAMP will provide AUM with access to ongoing oncology research and drug development in the Indian biotechnology arena through its existing networks, and will pair that with AUM’s rich experience in early drug development. CCAMP will also provide AUM with assistance in IP filing, MTA agreements etc. By tapping on each party’s strengths, this symbiotic partnership hopes to advance India-discovered and developed small molecules as drugs for cancer therapy for patients in need across the world.

The partnership creates an avenue for Early Phase commercial exit for C-CAMP’s existing startups in the oncology space that share AUM’s mandate and vision by making way to license out their technologies. AUM has committed to offer its support to C-CAMP’s existing start-ups, in line with Start-up India and Skill India initiatives by the Indian government. AUM Biosciences offers world-class drug development and regulatory strategies designed to rapidly move candidate molecules along the drug development pathway.

Welcoming the formalization of AUM’s incubation at C-CAMP, Dr. Taslimarif Saiyed, CEO & Director, C-CAMP said “ Cancer continues to be a huge healthcare burden across India and impacts both livelihood at the personal level and economy at the national. C-Camp is looking forward to having AUM as its international incubatee and supporting AUM’s efforts in building new cancer therapeutics. We hope that this partnership will also allow global collaborations for Indian academia and startups.”.

AUM was found on the foundation of developing drugs in “Asia for global”. We are committed to working with C-CAMP to support the various initiatives by the Indian government. This partnership will enable us to leverage on AUM’s therapeutic innovation expertise to identify, develop novel cancer treatments in Asia,” Vishal Doshi, Founder and CEO, AUM Biosciences.

About C-CAMP:

Partnership with The Centre for Cellular and Molecular Platforms (C-CAMP) - AUM has partnered with C-CAMP, India’s premier bio-innovation hub to further strengthen our focus on the pre-clinical development of small molecules as anti-cancer drugs.

With this collaboration, AUM will have access to ongoing oncology research and drug development in the Indian biotechnology arena and jointly develop small molecules as drugs for cancer therapy for patients in need across the world. This is a unique partnership which will benefit both the organisations in the R&D front and commercial front.

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

Led by a highly-experienced management team with over 70 years of oncology drug development experience combined, AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com